摘要
目的观察利妥昔单抗联合沙利度胺对淋巴瘤患者炎性因子及肿瘤标志物水平的影响。方法将88例淋巴瘤患者随机分为对照组与观察组,各44例。两组均经常规化疗治疗,同时,对照组给予利妥昔单抗,观察组在对照组基础上给予沙利度胺。比较两组的临床效果。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗后,两组的IL-6、IL-17、TNF-α、PDGF-BB、VEGF及LRG1水平均降低,且观察组低于对照组(P<0.05)。两组的各不良反应发生率无显著差异(P>0.05)。结论利妥昔单抗联合沙利度胺治疗淋巴瘤的效果显著,可降低炎性因子及肿瘤标志物水平,且安全性高。
Objective To observe the effects of rituximab combined with thalidomide on inflammatory factors and tumor markers levels in patients with lymphoma.Methods A total of 88 patients with lymphoma were randomly divided into control group and observation group,with 44 cases in each group.Both groups were treated with conventional chemotherapy,at the same time,the control group was given rituximab,and the observation group was given thalidomide on the basis of the control group.The clinical effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the levels of IL-6,IL-17,TNF-α,PDGF-BB,VEGF and LRG1 in the two groups decreased,and those in the observation group were lower than the control group(P<0.05).There were no significant differences in the incidences of each adverse reactions between the two groups(P>0.05).Conclusion Rituximab combined with thalidomide in the treatment of lymphoma has significant effect,it can reduce the levels of inflammatory factors and tumor markers,and has high safety.
作者
丁梦杰
DING Mengjie(Oncology Department,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China)
出处
《临床医学研究与实践》
2020年第36期41-42,45,共3页
Clinical Research and Practice
